Cargando…

Shikonin Prolongs Allograft Survival via Induction of CD4(+)FoxP3(+) Regulatory T Cells

A transplanted organ is usually rejected without any major immunosuppressive treatment because of vigorous alloimmune responsiveness. However, continuous global immunosuppression may cause severe side effects, including nephrotoxicity, tumors, and infections. Therefore, it is necessary to seek novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Qiaohuang, Qiu, Feifei, Chen, Yuchao, Liu, Cuihua, Liu, Huazhen, Liang, Chun-Ling, Zhang, Qunfang, Dai, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451963/
https://www.ncbi.nlm.nih.gov/pubmed/30988670
http://dx.doi.org/10.3389/fimmu.2019.00652
_version_ 1783409246611701760
author Zeng, Qiaohuang
Qiu, Feifei
Chen, Yuchao
Liu, Cuihua
Liu, Huazhen
Liang, Chun-Ling
Zhang, Qunfang
Dai, Zhenhua
author_facet Zeng, Qiaohuang
Qiu, Feifei
Chen, Yuchao
Liu, Cuihua
Liu, Huazhen
Liang, Chun-Ling
Zhang, Qunfang
Dai, Zhenhua
author_sort Zeng, Qiaohuang
collection PubMed
description A transplanted organ is usually rejected without any major immunosuppressive treatment because of vigorous alloimmune responsiveness. However, continuous global immunosuppression may cause severe side effects, including nephrotoxicity, tumors, and infections. Therefore, it is necessary to seek novel immunosuppressive agents, especially natural ingredients that may provide sufficient efficacy in immunosuppression with minimal side effects. Shikonin is a bioactive naphthoquinone pigment, an ingredient originally extracted from the root of Lithospermum erythrorhizon. Previous studies have shown that shikonin regulates immunity and exerts anti-inflammatory effects. In particular, it can ameliorate arthritis in animal models. However, it is unclear whether shikonin inhibits alloimmunity or allograft rejection. In this study and for the first time, we demonstrated that shikonin significantly prolonged the survival of skin allografts in wild-type mice. Shikonin increased the frequencies of CD4(+)Foxp3(+) regulatory T cells (Tregs) post-transplantation and induced CD4(+)Foxp3(+) Tregs in vitro as well. Importantly, depleting the Tregs abrogated the extension of skin allograft survival induced by shikonin. It also decreased the frequencies of CD8(+)CD44(high)CD62L(low) effector T cells and CD11c(+)CD80(+)/CD11c(+)CD86(+) mature DCs after transplantation. Moreover, we found that shikonin inhibited the proliferation of T cells in vitro and suppressed their mTOR signaling. It also reduced the gene expression of pro-inflammatory cytokines, including IFNγ, IL-6, TNFα, and IL-17A, while increasing the gene expression of anti-inflammatory mediators IL-10, TGF-β1, and indoleamine-2, 3-dioxygenase (IDO) in skin allografts. Further, shikonin downregulated IDO protein expression in skin allografts and DCs in vitro. Taken together, shikonin inhibits allograft rejection via upregulating CD4(+)Foxp3(+) Tregs. Thus, shikonin is a novel immunosuppressant that could be potentially used in clinical transplantation.
format Online
Article
Text
id pubmed-6451963
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64519632019-04-15 Shikonin Prolongs Allograft Survival via Induction of CD4(+)FoxP3(+) Regulatory T Cells Zeng, Qiaohuang Qiu, Feifei Chen, Yuchao Liu, Cuihua Liu, Huazhen Liang, Chun-Ling Zhang, Qunfang Dai, Zhenhua Front Immunol Immunology A transplanted organ is usually rejected without any major immunosuppressive treatment because of vigorous alloimmune responsiveness. However, continuous global immunosuppression may cause severe side effects, including nephrotoxicity, tumors, and infections. Therefore, it is necessary to seek novel immunosuppressive agents, especially natural ingredients that may provide sufficient efficacy in immunosuppression with minimal side effects. Shikonin is a bioactive naphthoquinone pigment, an ingredient originally extracted from the root of Lithospermum erythrorhizon. Previous studies have shown that shikonin regulates immunity and exerts anti-inflammatory effects. In particular, it can ameliorate arthritis in animal models. However, it is unclear whether shikonin inhibits alloimmunity or allograft rejection. In this study and for the first time, we demonstrated that shikonin significantly prolonged the survival of skin allografts in wild-type mice. Shikonin increased the frequencies of CD4(+)Foxp3(+) regulatory T cells (Tregs) post-transplantation and induced CD4(+)Foxp3(+) Tregs in vitro as well. Importantly, depleting the Tregs abrogated the extension of skin allograft survival induced by shikonin. It also decreased the frequencies of CD8(+)CD44(high)CD62L(low) effector T cells and CD11c(+)CD80(+)/CD11c(+)CD86(+) mature DCs after transplantation. Moreover, we found that shikonin inhibited the proliferation of T cells in vitro and suppressed their mTOR signaling. It also reduced the gene expression of pro-inflammatory cytokines, including IFNγ, IL-6, TNFα, and IL-17A, while increasing the gene expression of anti-inflammatory mediators IL-10, TGF-β1, and indoleamine-2, 3-dioxygenase (IDO) in skin allografts. Further, shikonin downregulated IDO protein expression in skin allografts and DCs in vitro. Taken together, shikonin inhibits allograft rejection via upregulating CD4(+)Foxp3(+) Tregs. Thus, shikonin is a novel immunosuppressant that could be potentially used in clinical transplantation. Frontiers Media S.A. 2019-04-01 /pmc/articles/PMC6451963/ /pubmed/30988670 http://dx.doi.org/10.3389/fimmu.2019.00652 Text en Copyright © 2019 Zeng, Qiu, Chen, Liu, Liu, Liang, Zhang and Dai. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zeng, Qiaohuang
Qiu, Feifei
Chen, Yuchao
Liu, Cuihua
Liu, Huazhen
Liang, Chun-Ling
Zhang, Qunfang
Dai, Zhenhua
Shikonin Prolongs Allograft Survival via Induction of CD4(+)FoxP3(+) Regulatory T Cells
title Shikonin Prolongs Allograft Survival via Induction of CD4(+)FoxP3(+) Regulatory T Cells
title_full Shikonin Prolongs Allograft Survival via Induction of CD4(+)FoxP3(+) Regulatory T Cells
title_fullStr Shikonin Prolongs Allograft Survival via Induction of CD4(+)FoxP3(+) Regulatory T Cells
title_full_unstemmed Shikonin Prolongs Allograft Survival via Induction of CD4(+)FoxP3(+) Regulatory T Cells
title_short Shikonin Prolongs Allograft Survival via Induction of CD4(+)FoxP3(+) Regulatory T Cells
title_sort shikonin prolongs allograft survival via induction of cd4(+)foxp3(+) regulatory t cells
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451963/
https://www.ncbi.nlm.nih.gov/pubmed/30988670
http://dx.doi.org/10.3389/fimmu.2019.00652
work_keys_str_mv AT zengqiaohuang shikoninprolongsallograftsurvivalviainductionofcd4foxp3regulatorytcells
AT qiufeifei shikoninprolongsallograftsurvivalviainductionofcd4foxp3regulatorytcells
AT chenyuchao shikoninprolongsallograftsurvivalviainductionofcd4foxp3regulatorytcells
AT liucuihua shikoninprolongsallograftsurvivalviainductionofcd4foxp3regulatorytcells
AT liuhuazhen shikoninprolongsallograftsurvivalviainductionofcd4foxp3regulatorytcells
AT liangchunling shikoninprolongsallograftsurvivalviainductionofcd4foxp3regulatorytcells
AT zhangqunfang shikoninprolongsallograftsurvivalviainductionofcd4foxp3regulatorytcells
AT daizhenhua shikoninprolongsallograftsurvivalviainductionofcd4foxp3regulatorytcells